Biosimilars Forum Welcomes Henlius as Newest Member

December 12, 2024 -The Biosimilars Forum has announced Henlius (2696.HK), a global biopharmaceutical company, as its newest member. Henlius joins the Biosimilars Forum during a critical time for the U.S. biosimilars industry — as the Forum leads initiatives on behalf of the industry to make lower-cost, FDA-approved biosimilars accessible to patients that need them.

Henlius is a rapidly growing biopharmaceutical provider that develops, manufactures, and distributes leading mAb biologics in over 50 countries around the world, serving over 690,000 patients.

“Henlius is committed to working with our industry partners to advance our mission of providing patients around the world with high-quality, affordable, and effective biosimilar medicines,” said Ping Cao, CBO and Biosimilar Center of Excellence Business Unit Head at Henlius. “We are so excited to join the Forum at this critical impasse — where access and adoption of these medicines is necessary to lower costs and improve healthcare outcomes for patients.”

Lower-cost medicines are more important than ever. Nearly 30% of Americans say they have not taken their medication as prescribed due to unaffordable prices. Biosimilars are a bipartisan free-market competitive answer to lowering the cost of medicines for patients and their families. In fact, biosimilars have the potential to save $133 billion in U.S. health care spending by the end of 2025 if they are accessible to patients.  

“I am excited to welcome Henlius as the latest member of the Biosimilars Forum,” said Juliana M. Reed, Executive Director of the Biosimilars Forum. “Our Board of Directors and I look forward to collaborating with the Henlius team as we work to make biosimilars accessible to patients as lower-cost, safe, and effective options.”

For more information on the Biosimilars Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.